National Jewish Health

About: National Jewish Health is a healthcare organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: Asthma & T cell. The organization has 883 authors who have published 833 publications receiving 79201 citations. The organization is also known as: National Jewish Medical and Research Center.

Genetic predictor of efficacy of anti-asthmatic agents for improving pulmonary function

Abstract: The present invention relates to methods for determining and predicting the efficacy of therapeutics for the treatment of an individual with asthma based on that individual’s β2-adrenergic receptor. The invention finds particular applicability to the treatment of an individual with asthma with an inhaled corticosteroid or a leukotriene receptor antagonist who is homozygous for arginine at position 16 of the β2-adrenergic receptor.

Il-4-induced lipid mediators class switching in human normal mononuclear phagocytes.

Abstract: Leukotrienes (LT) are important molecules arising from arachidonic acid, knokn to play an important role in inflammatory reactions [1]. Their synthesis is limited to a restricted number of cell involved in the inflammatory response, such as mast cells, neutrophils, eosinophils and monocyte/macrophages.

Efficient Total Synthesis of 5-Oxo-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic Acid (5-Oxo-ETE), a Potent Proinflammatory Autacoid.

Abstract: The title eicosanoid was prepared in good overall yield via a convergent aldol strategy that obviates the need for HPLC separation of olefinic isomers.

Proceedings of the Americas Association of Sarcoidosis and Other Granulomatous Diseases (AASOG) 2017 annual meeting

Abstract: On April 7th and 8th, 2017; the Americas Association for Sarcoidosis and Other Granulomatous Diseases (AASOG) held its annual scientific conference titled "Combining Transformative Sarcoidosis Research and Outreach to Improve Health Disparities" at the Penn State Health, Hershey Campus Conference Center. Participants came from geographically diverse areas of the United States. The demographics of meeting speakers and attendees reflected the gender, racial and ethnic diversity of those who are engaged in the treatment of the disease. The AASOG meeting was held in conjunction with an FSR-sponsored sarcoidosis patient-physician conference, providing a unique forum to enhance communication between patients, providers and researchers. Cutting edge topics at the meeting included immunology, microbiome, genomics, and challenges in diagnosis and treatment of vulnerable populations. The meeting's clinical foci were neurosarcoidosis, fatigue, and small fiber neuropathy. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 91-94).